Prof. Omran and colleagues observed that, currently, biallelic mutations in 73 different genes have been linked to PCD, allowing a genetic diagnosis in approximately 60% of cases, and that management includes surveillance of pulmonary function, imaging, and microbiology of upper and lower airways, in addition to daily airway clearance and prompt antibiotic treatment of infections.
PCD is caused by impaired mucociliary clearance attributed to poor ciliary motility. Clinically, PCD is characterised by chronic airway infections and randomisation of the left/right body asymmetry. Dynein heavy chains are motor proteins of the outer dynein arms (ODAs) essential for ciliary motility. Human respiratory cilia contain different types of ODAs. ODAs type 1 contain the dynein heavy chains DNAH5 and DNAH11 and are located in the proximal axonemal compartment. ODAs type 2 contain DNAH5 and DNAH9 and are located in the distal axonemal compartment.
The investigators also emphasised that early referral to specialised centres using a multidisciplinary approach is likely to improve outcomes, but that, currently, evidence-based knowledge on PCD care âlet alone management guidelinesâ is missing. Research and clinical investigators, supported by European and North American patient support groups, have joined forces under the name of BESTCILIA, a European Commission-funded consortium dedicated to improve PCD care and knowledge. Core network programmes include the establishment of the international PCD registry, the generation of PCD quality of life questionnaires, and the first randomised controlled trial in PCD. The main goal of BESTCILIA is to characterise the clinical course and improve the diagnosis and treatment of PCD patients, and the organisation points to marked discrepancies among European countries in the availability of PCD diagnostic services. Prof. Omran further described how different gene mutations in motile cilia affect specific phenotypes including mucus clearing and heterotaxy/situs inversus, but also occasionally atypical phenotypes.
For example, Prof. Omran and colleagues recently identified loss-of-function mutations in DNAH9 in 5 independent families that cause situs abnormalities and heart defects and are associated with subtle respiratory ciliary dysfunction. Consistent with the observed subtle respiratory phenotype, high-speed video microscopy demonstrated distally impaired ciliary bending in DNAH9-mutant respiratory cilia, reflecting a subtle defect in clearance. Absence of DNAH9 results in absence of other ODA components such as DNAH5, DNAI1, and DNAI2 from the distal axonemal compartment. Although DNAH9-mutant respiratory cilia show a distal deficiency of ODA complexes, mucociliary clearance is not disturbed in these individuals. In contrast, absence of DNAH11, affecting the proximally located ODA type 1, results in disturbed mucociliary clearance and PCD. In vitro ciliogenesis cell culture experiments demonstrate that DNAH11 is first recruited to the ciliary axoneme during early ciliogenesis, while DNAH9 appears in later stages of ciliogenesis in the distal ciliary compartment.
While significant advances have been made with regard to understanding the aetiology of this disease, Prof. Omran concluded that multi-disciplinary collaboration is necessary to best diagnose these patients. Genetics and NO measurements are the most reliable means since nasal scrapings and high-speed videography quality differ between hospitals and are less robust.
Figure: Left to right: electron scanning microscopy of primary cilia in renal tubule tissue; confocal image of basal body (yellow) ciliary axoneme (red), and ciliary tip (green); histology staining of cilia in renal tubules; cilia in retina (yellow-green); multiciliated respiratory epithelial cell; ciliated neurons (green) in the nematode C. elegans. Photos on file.
- Omran H, et al. A7385, ATS 2019, 17-22 May, Dallas, USA.
Posted on
Previous Article
« Obstructive sleep apnoea affects morning spatial navigational memory processing in asymptomatic older individuals Next Article
Durability of culture conversion in patients receiving ALIS for treatment-refractory MAC lung disease »
« Obstructive sleep apnoea affects morning spatial navigational memory processing in asymptomatic older individuals Next Article
Durability of culture conversion in patients receiving ALIS for treatment-refractory MAC lung disease »
Table of Contents: ATS 2019
Featured articles
Letter from the Editor
Interview with Prof. Christian Bergmann
Treatable Traits in Chronic Inflammatory Airway Disease: Back to Basics
Treatable traits in chronic inflammatory airway disease: back to basics
Critical Care Medicine
Distinguishing between 4 different subtypes of sepsis sets the stage for individualised treatment
Stem cell therapy in acute respiratory distress syndrome improves 28-day mortality
SPICE III trial: Early sedation with dexmedetomidine in critically ill patients
SAATELLITE trial: Suvratoxumab prevents ventilator-associated Staphylococcus Aureus pneumonia in intensive care unit patients
Sleep Medicine
Million-patient study reveals gaps in long-term adherence among various sub-populations
Sleep apnoea severity has a non-linear relationship with acute myocardial infarction risk
Obstructive sleep apnoea affects morning spatial navigational memory processing in asymptomatic older individuals
Pulmonary Vascular Disease and Interstitial Lung Disease
Nintedanib reduces lung function decline in systemic sclerosis-associated ILD
Pulmonary arterial hypertension: early treatment with selexipag most effective
Long-term safety and efficacy of recombinant human pentraxin-2 in patients with idiopathic pulmonary fibrosis
Infection
Dupilumab improves outcomes in patients with severe chronic rhinosinusitis with nasal polyps and comorbid asthma
Durability of culture conversion in patients receiving ALIS for treatment-refractory MAC lung disease
E-cigarette use disrupts normal immune response to viral infections, particularly in women
Paediatric Pulmonary Medicine
Bacterial pneumonia predicts ongoing lung problems in infants hospitalised for acute respiratory failure
Aspergillus and early cystic fibrosis lung disease: does it need to be treated?
COPD
CORTICO-COP trial: eosinophil-guided therapy reduces systemic corticosteroid exposure
A randomised controlled trial of a smoking cessation smartphone application
Benralizumab does not ameliorate COPD exacerbations (GALATHEA/TERRANOVA trials)
Aclidinium bromide delays COPD exacerbation without increased MACE risk
Bench-to-Bedside (Pre-Clinical)
Human lung organoids to study foetal RSV infection
CRISPR/Cas9 genome editing therapy of hereditary pulmonary alveolar proteinosis
Cilia diagnostics in primary ciliary dyskinesia
Tuberous sclerosis complex 2 may be a novel target in pulmonary arterial hypertension therapy
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com